ArticleJournal of pharmaceutical sciences2014
Development and comparison of new high-efficiency dry powder inhalers for carrier-free formulations.
Article in Journal of pharmaceutical sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Development and characterization of an Indacaterol/Tiotropium Bromide composite dry powder inhalation formulation for COPD.Pharmaceutical science advances · 2026Article
- Inhaled Nanoparticulate Systems: Composition, Manufacture and Aerosol Delivery.Journal of aerosol medicine and pulmonary drug delivery · 2024Review
- A Quality by Design Framework for Capsule-Based Dry Powder Inhalers.Pharmaceutics · 2021Review
- Characterization of excipient enhanced growth (EEG) tobramycin dry powder aerosol formulations.International journal of pharmaceutics · 2020Article
- Development of Dry Powder Inhaler Patient Interfaces for Improved Aerosol Delivery to Children.AAPS PharmSciTech · 2020Article
- Computational Fluid Dynamics (CFD) Simulations of Spray Drying: Linking Drying Parameters with Experimental Aerosolization Performance.Pharmaceutical research · 2020Article
- Use of Computational Fluid Dynamics (CFD) Dispersion Parameters in the Development of a New DPI Actuated with Low Air Volumes.Pharmaceutical research · 2019Article
- Use of computational fluid dynamics deposition modeling in respiratory drug delivery.Expert opinion on drug delivery · 2019Review
- Understanding the Impacts of Surface Compositions on the In-Vitro Dissolution and Aerosolization of Co-Spray-Dried Composite Powder Formulations for Inhalation.Pharmaceutical research · 2018Article
- Efficient Nose-to-Lung Aerosol Delivery with an Inline DPI Requiring Low Actuation Air Volume.Pharmaceutical research · 2018Article
- Development of an Inline Dry Powder Inhaler That Requires Low Air Volume.Journal of aerosol medicine and pulmonary drug delivery · 2018Article
- Validating Whole-Airway CFD Predictions of DPI Aerosol Deposition at Multiple Flow Rates.Journal of aerosol medicine and pulmonary drug delivery · 2016Article
- Characterization of a New High-Dose Dry Powder Inhaler (DPI) Based on a Fluidized Bed Design.Annals of biomedical engineering · 2015Article
- Efficient Nose-to-Lung (N2L) Aerosol Delivery with a Dry Powder Inhaler.Journal of aerosol medicine and pulmonary drug delivery · 2015Article
- The acoustic features of inhalation can be used to quantify aerosol delivery from a Diskus™ dry powder inhaler.Pharmaceutical research · 2014Article
- Development of high efficiency ventilation bag actuated dry powder inhalers.International journal of pharmaceutics · 2014Article
- Performance of dry powder inhalers with single dosed capsules in preschool children and adults using improved upper airway models.Pharmaceutics · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
High-efficiency dry powder inhalers (DPIs) were developed and tested for use with carrier-free formulations across a range of different inhalation flow rates. Performance of a previously reported DPI was compared with two new designs in terms of emitted dose (ED) and aerosolization characteristics using in vitro experiments. The two new designs oriented the capsule chamber (CC) at different angles to the main flow passage, which contained a three-dimensional (3D) rod array for aerosol deaggregation. Computational fluid dynamics simulations of a previously developed deaggregation parameter, the nondimensional specific dissipation (NDSD), were used to explain device performance. Orienting the CC at 90° to the mouthpiece, the CC90 -3D inhaler provided the best performance with an ED = 73.4%, fine particle fractions (FPFs) less than 5 and 1 μm of 95.1% and 31.4%, respectively, and a mass median aerodynamic diameter (MMAD) = 1.5 μm. For the carrier-free formulation, deaggregation was primarily influenced by capsule aperture position and the NDSD parameter. The new CC-3D inhalers reduced the percent difference in FPF and MMAD between low and high flows by 1-2 orders of magnitude compared with current commercial devices. In conclusion, the new CC-3D inhalers produced extremely high-quality aerosols with little sensitivity to flow rate and are expected to deliver approximately 95% of the ED to the lungs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.